




TICK-BORNE ENCEPHALITIS (TBE) VACCINE

Susan Hills, MBBS, MTH
Medical Epidemiologist
Arboviral Diseases Branch
Centers for Disease Control and Prevention


January 12, 2022

Immunogenicity of 1 or 2 doses of TBE vaccine


Seropositivity after doses 1, 2, and 3 of primary series in adults




Seropositivity after doses 1, 2, and 3 of primary series in adults




Seropositivity after doses 1, 2, and 3 of primary series in adults




Seropositivity after doses 1, 2, and 3 of primary series in adults




Seropositivity after doses 1, 2, and 3 of primary series in adults



Geometric mean titers (GMTs) after doses 1, 2, and 3 in adults



Seropositivity and GMTs after doses 2 and 3 of primary series in children aged 1–11 years (N=129)



Summary of seropositivity rates and GMTs

- After 1 dose
 - Seropositivity rates and GMTs are low
- After dose 2
 - Seropositivity rates and GMTs initially increase then decrease in following months
 - Variability by age group with lower rates and GMTs in older age groups
 - Concerning that GMTs close to seropositivity cut off
- After dose 3
 - Increase in seropositivity rates and notable increase in GMTs

Work Group conclusions

- Important to recommend a 3-dose primary series be completed prior to departure, in line with FDA-approved schedule
- Include data on immunogenicity after 1 or 2 doses in MMWR to enable counseling of individual travelers unable to complete full series